Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Oxford
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Oxford, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2863 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:15 UTC
2863
Studies in scope
industry-sponsored, all four open statuses
1385
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2015 Manchester 668 Birmingham 478 Glasgow 437 Cambridge 425
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca20 Hoffmann-La Roche17 AbbVie17 Eli Lilly and Company15 Merck Sharp & Dohme LLC13
Site city
London2015 Manchester668 Birmingham478 Glasgow437 Cambridge425
All 429 cities
Target enrolment
to

Trials with a site in Oxford

372 of 2863 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Not yet open
Bristol-Myers Squibb
Phase 3
2,380
Birmingham, Cambridge, Edinburgh, London, Peterborough, Cottingham, Leeds, Oxford
2026-12-16
Not yet open
Novo Nordisk A/S
Phase 3
84
Birmingham, Cardiff, London, Oxford, Sheffield
2026-10-09
Recruiting
Charm Therapeutics
Phase 1
40
Oxford
2026-09-28
Recruiting
Boehringer Ingelheim
Phase 3
466
Birmingham, Exeter, Lancaster, Leeds, Leicester, London, Manchester, Oxford
2026-09-17
Recruiting
Incyte Corporation
Phase 3
426
Cambridge, Edinburgh, Harrow, Leeds, London, Newcastle upon Tyne, Oxford, Penzance
2026-09-08
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
NCT07587242Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Muscular Disorders, Atrophic, Muscular Disease
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 3
70
Newcastle, Oxford
2026-09-01
Recruiting
Kardigan, Inc.
Phase 3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-08-26
Recruiting
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
DrugN-Acetyl-L-Leucine
IntraBio Inc
Phase 3
60
Newcastle upon Tyne, Oxford
2026-08-17
Recruiting
Eli Lilly and Company
Phase 3
1,000
Bodmin, Edinburgh, Exeter, Glasgow, Liverpool, Motherwell, Oxford, Penzance
2026-08-14
Recruiting
Takeda
Phase 2
20
Oxford
2026-08-13
Not yet open
Entrada Therapeutics, Inc.
Phase 2
80
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2026-08
Recruiting
HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB
NCT07575308Von Willebrand Disease (VWD), Heavy Menstrual Bleeding (HMB)
DrugALN-6400
Alnylam Pharmaceuticals
Phase 2
24
Bradford, Oxford, Truro
2026-07-30
Recruiting
Amgen
Phase 2
15
Oxford
2026-07-21
Active, closed
Boehringer Ingelheim
Phase 2
344
Blackpool, Guisborough, High Wycombe, Leicester, Middlesbrough, Oxford
2026-06-30
Recruiting
AstraZeneca
Phase 1/2
152
Belfast, Fulham, Guildford, London, Newcastle upon Tyne, Oxford
2026-06-03
Recruiting
Eli Lilly and Company
Phase 3
252
Birmingham, Bristol, Cheadle, Lancaster, Lincoln, Newcastle, Oxford, Sheffield
2026-06-01
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
Leeds, Oxford
2026-05-28
Recruiting
Takeda
Phase 3
300
Leicester, Boston, Oxford, Birmingham, London, Manchester
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 3
138
London, Cardiff, Oxford
2026-05-15
Recruiting
Ipsen
Phase 3
350
Frimley, London, Norwich, Oxford, Cottingham, Aberdeen, Birmingham, Glasgow
2026-05-14
Recruiting
Incyte Corporation
Phase 1
218
London, Nottingham, Oxford
2026-05-11
Recruiting
AstraZeneca
Phase 3
420
Edinburgh, Hampshire, Leeds, London, Manchester, Nottingham, Oxford, Sutton
2026-05-05
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Antrim, Birmingham, Bristol, Cardiff, Exeter, London, Nottingham, Oxford
2026-05
Recruiting
AbbVie
Phase 2/3
900
Oxford
2026-04-30
Recruiting
Controlling Hyperactive Immunity With Long-lived Lymphocytes
NCT07473154Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA), Systemic Sclerosis (SSc), Autoimmune Rheumatologic Disease
Quell Therapeutics Limited
Phase 1/2
16
Birmingham, Leeds, London, Manchester, Newcastle, Oxford
2026-04-10
Recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
240
Brighton, Oxford
2026-03-31
Recruiting
Bristol-Myers Squibb
Phase 3
325
Exeter, London, Oxford, Chertsey, Sheffield, Crowborough, Motherwell
2026-03-25
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Exeter, Aberdeen, Cambridge, Cardiff, Glasgow, Leeds, London, Oxford
2026-03-24
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
London, Oxford, Sutton, Glasgow, Manchester
2026-03-13
Recruiting
Hoffmann-La Roche
Phase 2
80
Blackpool, Harlow, Northwood, Middlesex, Oxford
2026-02-18
Recruiting
Neurocrine Biosciences
Phase 2
120
London, Oxford
2026-02-16
Recruiting
Kardigan, Inc.
Phase 2/3
332
Bristol, Glasgow, Leicester, London, Oxford
2026-02-13
Recruiting
Eli Lilly and Company
Phase 3
1,000
Edinburgh, Exeter, Glasgow, London, Nottingham, Oxford, Penzance, Rotherham
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
300
Aberdeen, Birmingham, Bristol, Cambridge, Cardiff, Oxford, Southampton
2026-02-05
Recruiting
AstraZeneca
Phase 3
2,130
Cambridge, Dundee, Leeds, London, Manchester, Oxford
2026-02-03
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Birmingham, Edgbaston, Trumpington, Exeter, Oxford, Edinburgh, London
2026-02-02
Recruiting
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07096778Multiple Myeloma Refractory, Multiple Myeloma in Relapse
DrugsPomalidomide·Dexamethasone
CellCentric Ltd.
Phase 2
100
Withington, Sutton, Cardiff, Bebington, Edinburgh, London, Oxford, Southampton
2026-01-22
Recruiting
CSL Behring
Phase 2
84
Glasgow, Belfast, Bristol, Liverpool, London, Norwich, Nottingham, Oxford
2026-01-22
Recruiting
Eli Lilly and Company
Phase 3
150
Birmingham, Cambridge, Cardiff, Glasgow, London, Oxford, Southampton
2026-01-12
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Norwich, Manchester, Metropolitan Borough of Wirral, Oxford, Guildford, Birmingham, Cardiff, Dorchester
2025-12-31
Recruiting
argenx
Phase 2
60
Cambridge, London, Oxford, Sheffield, Glasgow, Birmingham, Leeds
2025-12-19
Recruiting
Draig Therapeutics Ltd
Phase 2
300
Chester, Eastbourne, Glasgow, London, Nottingham, Oxford
2025-12-16
Recruiting
Angitia Incorporated Limited
Phase 2
80
Cambridge, Edinburgh, London, Oxford
2025-12-12
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
Cambridge, Cardiff, Edinburgh, Liverpool, London, Nottingham, Oxford
2025-11-25
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Oxford, Aberdeen, Derby, Lincoln, London, Southampton, Sutton
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Dundee, Exeter, London, Newcastle, Oxford, Plymouth,Devon
2025-11-24
Recruiting
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
London, Oxford, Birmingham, Cardiff, Glasgow, Sheffield, Southampton
2025-11-19
Active, closed
Eli Lilly and Company
Phase 3
250
Birmingham, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford, Penzance
2025-11-17
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Bath, Birmingham, Edinburgh, Glasgow, London, Manchester, Oxford, Preston
2025-11-12
Recruiting
BioNTech SE
Phase 3
558
Brighton, Bristol, Cottingham, Edinburgh, Leeds, London, Oxford, Rhyl
2025-10-30
Recruiting
Hoffmann-La Roche
Phase 3
600
Blackpool, Bristol, Canterbury, Cardiff, Hull, London, Maidstone, Oxford
2025-10-24
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
London, Oxford
2025-10-17
Recruiting
Sanofi
Phase 2
54
Cambridge, Oxford
2025-10-14
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 2
60
London, Oxford
2025-10-13
Recruiting
Bristol-Myers Squibb
Observational
223
Oxford, Bath, Wolverhampton, London
2025-10-08
Recruiting
Imbria Pharmaceuticals, Inc.
Phase 2
165
London, Glasgow, Oxford
2025-10-06
Recruiting
Genentech, Inc.
Phase 2
224
London, Liverpool, Oxford, Cambridge
2025-09-29
Recruiting
Sanofi
Phase 3
124
London, Norwich, Oxford
2025-09-26
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Oxford
2025-09-22
Recruiting
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Oxford
2025-08-30
Recruiting
Pfizer
Phase 3
6,000
Bristol, London, Manchester, Truro, Southampton, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
Scarcell Therapeutics S.A.S.
Phase 1
15
Oxford
2025-08-14
Recruiting
Perspectum
Observational
50
Oxford
2025-08-14
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
CSL Behring
Phase 3
20
London, Oxford
2025-07-28
Recruiting
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT06943755Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
DrugsZanzalintinib·Everolimus
Exelixis
Phase 2/3
440
Birmingham, Cardiff, Glasgow, Liverpool, London, Oxford, Sheffield, Sutton
2025-07-21
Recruiting
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
477
Birmingham, London, Oxford, Coventry, Cardiff, Manchester
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
Aberdeen, Edinburgh, Southampton, London, Oxford, Bath, Birmingham
2025-07-16
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Oxford, Sutton, Windsor, London
2025-07-01
Not yet open
GyroGlove Use in Essential Tremor Patients
NCT05958030Essential Tremor
GyroGear Ltd
Not applicable
30
Cambridge, Newcastle, Oxford
2025-07
Recruiting
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2025-06-30
Active, closed
Calluna Pharma AS
Phase 2
150
Birmingham, Edinburgh, Leeds, London, Manchester, Newcastle upon Tyne, Oxford, Southampton
2025-06-20
Recruiting
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Active, closed
AbbVie
Phase 3
573
London, North Finchley, Glasgow, Manchester, Oxford, Birmingham, Stockport
2025-06-17
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 3
156
London, Oxford
2025-06-10
Recruiting
Nova Laboratories Limited
Observational
180
Basildon, Cardiff, London, Manchester, Oxford
2025-06-09
Active, closed
Biogen
Phase 3
255
London, Oxford, Sheffield
2025-06-09
Recruiting
BONESUPPORT AB
Observational
128
Oxford
2025-06-02
Active, closed
Swedish Orphan Biovitrum
Phase 2
156
Leeds, London, Oxford
2025-05-28
Active, closed
Upstream Bio Inc.
Phase 2
396
Cottingham, Glasgow, Chertsey, Perth, Bradford, Oxford
2025-05-21
Recruiting
Eli Lilly and Company
Phase 4
279
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
NCT06876649Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma
DrugPirtobrutinib
Eli Lilly and Company
Phase 4
787
Leeds, Oxford, Plymouth
2025-05-20
Recruiting
Astellas Gene Therapies
Observational
50
Leeds, London, Oxford
2025-05-19
Recruiting
SecuraBio
Phase 3
124
Sutton, Glasgow, Leicester, London, Manchester, Nottingham, Oxford
2025-05-19
Recruiting
Akrivia Health
Observational
50,000
Oxford
2025-05-16
Recruiting
Mediar Therapeutics
Phase 2
164
Birmingham, Cambridge, Edinburgh, Oxford
2025-05-05
Recruiting
AbbVie
Phase 2
390
London, Oxford, Sutton, Manchester
2025-04-24
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Cottingham, Oxford, Birmingham, Cambridge, Leicester, London
2025-04-17
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Bristol, Aylesbury, Exeter, Plymouth, Middlesbrough, Lincoln, London, Oxford
2025-04-11
Recruiting
AstraZeneca
Phase 3
830
Blackpool, Glasgow, Guildford, Hull, Northwood, Oxford
2025-04-10
Recruiting
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
By invitation
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
NCT06859099Polyneuropathy, Inflammatory Demyelinating, Chronic
DrugRiliprubart
Sanofi
Phase 3
300
Oxford
2025-04-01
Recruiting
Accession Therapeutics Limited
Phase 1/2
72
Glasgow, Cardiff, Leeds, Oxford
2025-03-21
Recruiting
Daiichi Sankyo
Phase 3
582
Cambridge, London, Manchester, Oxford, Sheffield
2025-03-19
Recruiting
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
Recruiting
Takeda
Phase 3
600
London, Coventry, Bradford, Harlow, Oxford, Stoke-on-Trent, Wolverhampton
2025-03-10
Active, closed
Eli Lilly and Company
Phase 3
643
Birmingham, Blackburn, Blackpool, Bradford on Avon, Bromborough, Cheadle, Hounslow, Oxford
2025-03-05
Recruiting
SharpTx
Not applicable
170
Exeter, Preston, Oxford, Taunton, London
2025-02-20
Active, closed
Sanofi
Phase 3
231
London, Oxford, Bradford, Newcastle upon Tyne
2025-02-12
Recruiting
Janssen Research & Development, LLC
Phase 3
50
Birmingham, Liverpool, London, Oxford
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Manchester, Oxford
2025-02-10
Active, closed
AbbVie
Phase 3
468
Poole, Brighton, London, Thetford, Oxford
2025-02-10
Recruiting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment
DrugAcalabrutinib
AstraZeneca
Phase 4
60
Bournemouth, Oxford, Plymouth, Romford, Stockton, Sutton Coldfield
2025-02-04
Recruiting
BioNTech SE
Phase 3
621
Manchester, Chelsea, Sutton, Huddersfield, Newcastle upon Tyne, Nottingham, Oxford, Dundee
2025-02-03
By invitation
Pharvaris Netherlands B.V.
Phase 3
170
Birmingham, Brighton, Bristol, Cambridge, Frimley, London, Oxford, Plymouth
2025-02-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Derriford, London, Oxford, Southampton
2025-01-30
Recruiting
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
NCT06789172Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer
DrugFamotidine
Epkin
Phase 1
146
Glasgow, Leicester, London, Manchester, Oxford
2025-01-23
Recruiting
Immatics US, Inc.
Phase 3
360
Cambridge, Glasgow, London, Manchester, Oxford, Southampton
2025-01-14
Not yet open
Microvisk Continuous Blood Donation Study
NCT06648837Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis, Atrial Fibrillation (AF)
Microvisk Technologies Ltd
Not applicable
2,500
Oxford
2025-01-13
Recruiting
Italfarmaco
Phase 2
18
Leeds, London, Newcastle upon Tyne, Oxford
2025-01-02
Recruiting
Sanofi
Phase 2
84
Leicester, Salford, Oxford
2024-12-19
Active, closed
argenx
Phase 3
154
Glasgow, Oxford, Salford, Sheffield, Taunton
2024-12-18
Recruiting
GlaxoSmithKline
Phase 3
520
Leicester, Middlesbrough, Oxford, Plymouth, Wolverhampton
2024-12-16
Active, closed
AbbVie
Phase 2
185
London, Oxford, Birmingham, Dundee
2024-12-13
Active, closed
Vicore Pharma AB
Phase 2
378
Birmingham, Exeter, London, Manchester, Oxford
2024-12-09
Active, closed
H. Lundbeck A/S
Phase 3
401
Salford, Oxford, Glasgow, Newcastle upon Tyne, Exeter, London
2024-12-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,082
Bristol, Exeter, Newcastle, Norwich, Northamptonshire, Bicester, Oxford, Somerset
2024-12-02
Active, closed
Pharvaris Netherlands B.V.
Phase 3
81
London, Birmingham, Bristol, Cambridge, Frimley, Leeds, Oxford, Plymouth
2024-12-01
Active, closed
Novartis Pharmaceuticals
Phase 4
24
Cambridge, London, Oxford, Salford
2024-11-25
Active, closed
Daiichi Sankyo
Phase 3
700
Birmingham, Harrow, London, Maidstone, Manchester, Oxford, Torquay
2024-11-19
Active, closed
Sanofi
Phase 2
556
Ruislip, Corby, Nottingham, Oxford, Barnsley, Bradford, London
2024-11-07
Recruiting
Takeda
Phase 3
24
London, Oxford
2024-11-06
Recruiting
J-Valve Transfemoral Pivotal Study
NCT06455787Aortic Valve Regurgitation, Aortic Valve Disease Mixed
JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
Not applicable
194
Oxford
2024-10-17
Recruiting
Alnylam Pharmaceuticals
Phase 1
66
Birmingham, Cambridge, Cardiff, Glasgow, Greater Manchester, London, Oxford, Plymouth
2024-10-14
Active, closed
Merck Sharp & Dohme LLC
Phase 2
66
Bodelwyddan, London, Oxford, Manchester
2024-10-14
Recruiting
Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase 1
256
London, Oxford
2024-10-03
Recruiting
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
NCT06569602Tricuspid Valve Regurgitation, Heart Valve Diseases, Cardiovascular Diseases
Edwards Lifesciences
Observational
500
Oxford
2024-10-01
Active, closed
argenx
Phase 1
15
Belfast, Oxford
2024-09-24
Recruiting
Theolytics Limited
Phase 1/2
44
Glasgow, London, Oxford
2024-09-24
Active, closed
Dianthus Therapeutics
Phase 2
46
London, Oxford, Salford
2024-09-17
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
London, Maidstone, Middlesbrough, Oxford, Sheffield, Birmingham, Bradford, Bristol
2024-09-11
Recruiting
AbbVie
Phase 2
590
Edinburgh, Glasgow, London, Oxford, Coventry, Wolverhampton, Bristol, Cardiff
2024-09-04
Active, closed
Sanofi
Phase 2
229
Oxford, Sheffield
2024-08-29
Recruiting
Prevail Therapeutics
Phase 1
124
Southampton, Oxford
2024-08-27
Recruiting
Sanofi
Phase 3
160
London, Inverness, Oxford
2024-08-21
Recruiting
Carrick Therapeutics Limited
Phase 1/2
50
Manchester, Oxford, Sutton
2024-08-16
Recruiting
Jazz Pharmaceuticals
Phase 3
550
Bath, Glasgow, Leicester, London, Manchester, Oxford, Wolverhampton
2024-08-13
Active, closed
Incyte Corporation
Phase 1
37
London, Oxford
2024-08-08
Recruiting
AstraZeneca
Phase 3
788
Cambridge, Guildford, London, Manchester, Oxford, Swansea, Taunton, Truro
2024-08-01
Active, closed
Ultragenyx Pharmaceutical Inc
Phase 3
255
Cambridge, London, Oxford
2024-07-31
By invitation
Biohaven Therapeutics Ltd.
Phase 2
660
Swansea, Glasgow, Salford, Liverpool, Oxford, Cardiff, London, Newcastle upon Tyne
2024-07-30
Active, closed
Janssen Pharmaceutica N.V., Belgium
Phase 2
55
Bath, Birmingham, Bristol, Edinburgh, Guildford, London, Oxford, Plymouth
2024-07-22
Recruiting
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
DrugIvosidenib
Servier Bio-Innovation LLC
Phase 3
136
Edinburgh, London, Manchester, Oxford
2024-07-09
Recruiting
argenx
Phase 2/3
12
Oxford
2024-06-28
Recruiting
Immunocore Ltd
Phase 3
680
Birmingham, Cambridge, Glasgow, Liverpool, London, Manchester, Oxford, Surrey Quays
2024-06-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Cambridge, Exeter, Doncaster, Huddersfield, London, Southampton, Oxford, Bristol
2024-06-05
Recruiting
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
NCT06419374Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
DrugPegozafermin
89bio, Inc.
Phase 3
762
Aberdeen, Bristol, Leeds, London, Oxford, Plymouth, Port Talbot, Portsmouth
2024-05-24
Active, closed
Biohaven Therapeutics Ltd.
Phase 2/3
390
Swansea, Glasgow, Salford, Oxford, Cardiff, London, Newcastle upon Tyne
2024-05-13
Active, closed
Pfizer
Observational
360
Glasgow, Nottingham, Oxford, Edinburgh, Crumpsall, Kent, London, Newport
2024-05-08
Active, closed
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
DrugTeriflunomide
Sanofi
Phase 3
2,500
Exeter, Kent, London, Swansea, Nottingham, Oxford, Cardiff, Bristol
2024-04-16
Active, closed
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
DrugPirfenidone
Avalyn Pharma Inc.
Phase 2
375
Cottingham, Birmingham, Glenfield, London, Londonderry, Oxford, Exeter, Wolverhampton
2024-04-03
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Cambridge, Northwood, London, Oxford, Newcastle upon Tyne
2024-04-03
Recruiting
Splice Bio
Observational
75
London, Leeds, Manchester, Oxford
2024-03-29
Recruiting
Italfarmaco
Phase 3
220
Belfast, Boston, London, Milton Keynes, Oxford, Southampton
2024-03-26
Recruiting
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer
Iambic Therapeutics, Inc
Phase 1
383
Chelsea, Oxford, Sutton
2024-03-25
Active, closed
AbbVie
Phase 2
156
Cambridge, Glasgow, London, Oxford
2024-03-23
Active, closed
Beacon Therapeutics
Phase 2/3
85
London, Oxford
2024-03-14
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Glasgow, London, Manchester, Oxford, Sheffield
2024-03-13
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
89bio, Inc.
Phase 3
1,350
High Wycombe, Bristol, Glasgow, Hull, London, Oxford, Portsmouth, Preston
2024-03-13
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
MacroGenics
Phase 1
250
Oxford, Sutton
2024-03-06
Active, closed
AstraZeneca
Phase 3
594
Cambridge, London, Manchester, Oxford, Taunton
2024-03-04
Recruiting
Italfarmaco
Phase 3
138
Newcastle upon Tyne, Oxford, Glasgow
2024-02-19
Recruiting
argenx
Observational
100
Dundonald, Oxford
2024-02-13
Recruiting
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
NCT06137144Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL)
DrugsAZD3470·Keytruda·Pembrolizumab
AstraZeneca
Phase 1/2
161
Manchester, Oxford
2024-01-23
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
London, Oxford, Southhampton
2023-12-27
Recruiting
Improving CRT Outcome With Non-Invasive Cardiac Mapping
NCT05564793Heart Failure With Reduced Ejection Fraction
EP Solutions SA
Not applicable
330
London, Oxford
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 3
120
Birmingham, Leeds, London, Manchester, Oxford
2023-12-20
Recruiting
Janssen Research & Development, LLC
Phase 1
300
London, Oxford
2023-12-20
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,314
Cambridge, Derby, Torquay, Northwood, Truro, Glasgow, London, Oxford
2023-12-18
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Bristol, Lancaster, London, Oxford, Newmarket, Windsor, Barnet, Leeds
2023-12-13
Recruiting
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin
AstraZeneca
Phase 2
226
Glasgow, Leeds, London, Oxford
2023-12-13
Active, closed
Syndax Pharmaceuticals
Phase 2
145
Cambridge, Norwich, Oxford, Perth, Leeds, Birmingham
2023-12-11
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Oxford
2023-12-07
Active, closed
argenx
Observational
413
Bristol, Fulwood, Glasgow, Nottingham, Oxford, Salford, Sheffield, Taunton
2023-11-29
Active, closed
Hoffmann-La Roche
Phase 2
13
London, Oxford
2023-11-29
Active, closed
Genentech, Inc.
Phase 1
65
Cambridge, Leicester, London, Oxford, Sutton
2023-11-27
Recruiting
AstraZeneca
Phase 3
625
Cardiff, Chelsea, Leicester, Liverpool, London, Oxford, Surrey, Sutton
2023-11-23
Active, closed
AstraZeneca
Phase 3
1,902
Birmingham, Cardiff, Lancaster, London, Northampton, Oxford, Taunton
2023-11-14
Active, closed
Xentria, Inc.
Phase 1/2
32
Coventry, London, Norwich, Oxford, Perth
2023-11-10
Active, closed
Syntara
Phase 2
40
Oxford
2023-11-08
Active, closed
Bristol-Myers Squibb
Phase 2
227
Harrow, North Shields, Leeds, Bristol, Dundee, London, Oxford, Stockton-on-Tees
2023-11-07
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Birmingham, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough, Exeter
2023-10-25
By invitation
Eledon Pharmaceuticals
Phase 2
132
Oxford
2023-10-25
Recruiting
Hoffmann-La Roche
Phase 3
182
Glasgow, Lincoln, London, Manchester, Oxford, Plymouth
2023-10-22
Recruiting
AbbVie
Phase 3
1,500
High Wycombe, Brighton, Gloucester, London, Oxford, Harrow, Salford
2023-10-11
By invitation
Sarepta Therapeutics, Inc.
Phase 3
400
London, Oxford, Newcastle upon Tyne
2023-09-27
Active, closed
Incyte Corporation
Phase 1
160
London, Manchester, Oxford
2023-09-25
Active, closed
PharmaMar
Phase 3
469
Birmingham, Cambridge, Liverpool, London, Manchester, Oxford
2023-09-21
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Birmingham, Bristol, Cambridge, Dundee, Edinburgh, London, Oxford, Peterborough
2023-09-14
Recruiting
Hoffmann-La Roche
Phase 3
230
Belfast, Blackpool, Colchester, Essex, Northwood, Nottingham, Oxford
2023-09-08
Recruiting
Gilead Sciences
Phase 3
402
Hull, Ipswich, Leeds, London, Newcastle upon Tyne, Oxford, Sheffield, Wolverhampton
2023-09-07
Active, closed
Cytokinetics
Phase 3
500
Dundee, Glasgow, Liverpool, London, Oxford
2023-08-31
Recruiting
Atsena Therapeutics Inc.
Phase 3
97
Oxford
2023-08-22
Active, closed
Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)
NCT05987527Kidney Transplant Rejection, End Stage Renal Disease
Sangamo Therapeutics
Observational
11
Oxford
2023-08-15
Recruiting
Novian Health Inc.
Not applicable
122
London, Oxford
2023-08-09
Active, closed
Hoffmann-La Roche
Phase 3
459
Cambridge, Leicester, London, Oxford, Salford
2023-08-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,089
Bristol, Cambridge, Cringleford, London, Edinburgh, Oxford, Leeds, Manchester
2023-07-19
Recruiting
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
DrugRilvegostomig
AstraZeneca
Phase 1/2
392
Dundee, London, Metropolitan Borough of Wirral, Oxford
2023-07-11
Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
NCT05985655Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Phase 1/2
230
Glasgow, London, Manchester, Newcastle upon Tyne, Oxford
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 1
123
London, Oxford
2023-06-27
Recruiting
GlaxoSmithKline
Phase 1/2
123
Leicester, Oxford, Plymouth
2023-06-14
Active, closed
Alfasigma S.p.A.
Observational
509
Belfast, Bury, Exeter, Glasgow, London, Norwich, Oxford, Southampton
2023-06-12
Active, closed
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
NCT05778071Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
Alexion Pharmaceuticals, Inc.
Phase 3
165
Leicester, Norwich, Oxford
2023-06-07
Active, closed
Sarepta Therapeutics, Inc.
Phase 3
148
London, Oxford, Newcastle upon Tyne
2023-05-31
Active, closed
Vertex Pharmaceuticals Incorporated
Phase 1/2
7
Newcastle upon Tyne, Oxford
2023-05-16
Recruiting
MJN Neuroserveis, S.L
Observational
130
Oxford
2023-05-01
By invitation
An Open-label Study of XEN1101 in Epilepsy
NCT05718817Focal Epilepsy, Tonic-Clonic Seizures
DrugAzetukalner
Xenon Pharmaceuticals Inc.
Phase 3
880
Leeds, Cardiff, Birmingham, London, Oxford, Salford
2023-04-25
Active, closed
Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab
NCT05626855Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 2, SMA
DrugApitegromab
Scholar Rock, Inc.
Phase 3
238
Leeds, London, Oxford
2023-04-17
Active, closed
Umecrine Cognition AB
Phase 1/2
202
Birmingham, Glasgow, London, Newcastle, Nottingham, Oxford, Portsmouth, Wolverhampton
2023-04-14
Active, closed
Thoraflex Hybrid and Relay Extension Post-Approval Study
NCT05639400Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm
Vascutek Ltd.
Observational
352
Bristol, Oxford, Southampton
2023-03-17
Active, closed
DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma, Pediatric Low-grade Glioma
DrugsTovorafenib·Carboplatin
Day One Biopharmaceuticals, Inc.
Phase 3
418
Birmingham, Leeds, Liverpool, Manchester, Newcastle upon Tyne, Oxford, Southampton, Belfast
2023-02-27
Recruiting
Boehringer Ingelheim
Phase 1
66
London, Oxford, Sutton
2023-02-24
Recruiting
Xenon Pharmaceuticals Inc.
Phase 3
160
Cardiff, Wakefield, London, Oxford, Salford
2023-02-14
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease
Vico Therapeutics B. V.
Phase 1/2
68
London, Oxford
2023-02-14
Active, closed
Hoffmann-La Roche
Phase 2
301
Birmingham, Cambridge, Leeds, London, Oxford, Southampton
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
London, Oxford
2023-02-02
Active, closed
argenx
Phase 2
51
Glasgow, Oxford
2023-01-18
Recruiting
AstraZeneca
Phase 2
163
Edinburgh, Leeds, London, Oxford
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
513
London, Central Middlesbrough, Oxford
2023-01-12
Active, closed
Zenas BioPharma (USA), LLC
Phase 3
194
Oxford
2023-01-09
Recruiting
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
NCT05701917Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome
Inari Medical
Not applicable
300
London, Newcastle upon Tyne, Oxford
2023-01-06
Recruiting
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
NCT05378347Abdominal Aortic Aneurysm, Abdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder), Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)
Medtronic Cardiovascular
Not applicable
600
Oxford, Edinburgh
2023-01-05
By invitation
BioMarin Pharmaceutical
Observational
172
Cambridge, Glasgow, London, Oxford, Southampton
2023-01-01
Active, closed
AriBio Co., Ltd.
Phase 3
1,535
Cambridge, Cornwell, Exeter, London, Motherwell, Oxford, Southampton
2022-12-23
Recruiting
Iperboreal Pharma Srl
Phase 3
170
Birmingham, Bradford, Brighton, Canterbury, London, Oxford, Sheffield, Stoke-on-Trent
2022-12-14
Active, closed
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT05688280Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
DrugIP-001
Immunophotonics, Inc.
Phase 1/2
42
London, Oxford
2022-11-29
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 3
260
Liverpool, London, Oxford, Sheffield
2022-11-21
Recruiting
Pfizer
Phase 3
1,060
Leicester, London, Edinburgh, Oxford, Stoke-on-Trent, Birmingham, Cardiff, Glasgow
2022-11-10
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
87
Aberdeen, Edinburgh, London, Oxford
2022-11-07
Active, closed
Bayer
Phase 1
284
London, Oxford, Sutton, Newcastle upon Tyne
2022-11-04
Active, closed
Hoffmann-La Roche
Phase 1
121
Glasgow, London, Nottingham, Oxford
2022-10-26
Active, closed
Almirall, S.A.
Phase 4
447
London, Oxford, Poole, Weston-super-Mare
2022-10-24
Recruiting
Bristol-Myers Squibb
Phase 1/2
260
Manchester, Leicester, Liverpool, Oxford, London
2022-10-18
Active, closed
Kite, A Gilead Company
Phase 3
231
Birmingham, Cambridge, London, Manchester, Oxford, Southampton, Sutton
2022-09-22
Active, closed
The Euro-CRAFT Registry
NCT05805462Coronary Microvascular Disease
CoreAalst BV
Observational
671
Bath, Bristol, Essex, Glasgow, London, Oxford
2022-09-22
Active, closed
Genmab
Phase 3
549
Plymouth, Glasgow, London, Oxford, Leeds, Birmingham, Colchester, Liverpool
2022-09-20
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Belfast, Cambridge, Glasgow, High Wycombe, London, Oxford
2022-09-19
Active, closed
Redx Pharma Ltd
Phase 2
48
Belfast, Birmingham, Cambridge, Edinburgh, London, Londonderry, Oxford
2022-09-08
Recruiting
ModernaTX, Inc.
Phase 1/2
361
Preston, Glasgow, Birmingham, London, Manchester, Oxford, Southampton
2022-09-01
Recruiting
Asciminib Roll-over Study
NCT04877522Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DrugsAsciminib single agent·Bosutinib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 4
347
London, Oxford
2022-08-30
Active, closed
Biogen
Phase 2
416
London, Manchester, Southampton, Oxford, Sheffield, Motherwell, Birmingham, Bristol
2022-08-24
Active, closed
Adverum Biotechnologies, Inc.
Phase 2
69
London, Oxford
2022-08-23
By invitation
argenx
Phase 2/3
12
London, Oxford
2022-08-18
Active, closed
AbbVie
Observational
785
Exeter, Hull, Basingstoke, Bury, Kettering, Nottingham, Oxford, Belfast
2022-08-15
Recruiting
Step Pharma, SAS
Phase 1/2
180
Leicester, London, Manchester, Nottingham, Oxford, Plymouth, Sutton
2022-08-03
Active, closed
Janssen Research & Development, LLC
Phase 2
703
Belfast, Birmingham, Cambridge, Glasgow, High Wycombe, London, Oxford, Wolverhampton
2022-07-22
Active, closed
A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
NCT05458297Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
DrugsZilovertamab vedotin·Nemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
189
Truro, London, Oxford, Manchester
2022-07-21
Recruiting
Ionis Pharmaceuticals, Inc.
Phase 1
40
London, Oxford, Salford, Southampton
2022-07-21
Recruiting
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT05413850Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
Blue Earth Therapeutics Ltd
Phase 1/2
82
Bristol, Glasgow, London, Middlesbrough, Oxford, Sheffield, Southampton
2022-07-20
Active, closed
Biohaven Pharmaceuticals, Inc.
Phase 3
269
Glasgow, Oxford
2022-07-06
Active, closed
Merit Medical Systems, Inc.
Observational
500
Belfast, Birmingham, London, Oxford, Reading
2022-06-23
Active, closed
Celgene
Phase 3
939
Nottingham, Belfast Northern Ireland, Birmingham, Canterbury Kent, Lancashire Blackpool, London, Oxford, Portsmouth
2022-06-23
Recruiting
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
NCT05462106Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease
AC Immune SA
Phase 1/2
304
Cambridge, Liverpool, London, Oxford, Warrington
2022-06-21
Active, closed
ADC Therapeutics S.A.
Phase 1
154
London, Oxford
2022-06-17
Recruiting
Priothera SAS
Phase 3
366
Birmingham, Cardiff, Glasgow, London, Manchester, Newcastle upon Tyne, Nottingham, Oxford
2022-06-16
Active, closed
Hoffmann-La Roche
Phase 2/3
97
Birmingham, Oxford
2022-06-02
Active, closed
IO Biotech
Phase 3
407
London, Manchester, Oxford
2022-05-17
Recruiting
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
DrugBexobrutideg
Nurix Therapeutics, Inc.
Phase 1
572
Manchester, Glasgow, Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2022-04-13
Active, closed
Protagonist Therapeutics, Inc.
Phase 3
293
Uxbridge, Barnet, Boston, Harrow, London, Oxford
2022-04-01
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Nottingham, Oxford
2022-03-17
Recruiting
Hoffmann-La Roche
Phase 1
332
Manchester, Oxford
2022-03-07
Recruiting
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
NCT04988555Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
DrugsAzoles·Gilteritinib·Azacitidine·Venetoclax
Sumitomo Pharma America, Inc.
Phase 1/2
606
Birmingham, Bristol, Edinburgh, London, Manchester, Oxford, Stoke-on-Trent, Sutton
2022-02-28
Active, closed
Clinical Impact of the IBox As an Early Intervention TooL
NCT05112315Kidney Diseases, Kidney Disease, Chronic, Kidney Transplant Rejection, Kidney Transplant; Complications
Predict4Health
Not applicable
507
Birmingham, Leeds, London, Oxford
2022-02-18
Recruiting
Eledon Pharmaceuticals
Phase 1/2
48
Liverpool, Oxford
2022-02-18
By invitation
UCB Biopharma SRL
Phase 3
300
Birmingham, Glasgow, London, Oxford, Salford
2022-02-03
Active, closed
UCB Biopharma SRL
Phase 3
113
Liverpool, Oxford
2022-02-02
Active, closed
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD
DrugsEylea·Aflibercept
AbbVie
Phase 3
735
Aylesbury, London, Gloucester, Southampton, Oxford, Leeds, Bradford, Bristol
2022-01-13
Active, closed
Ionis Pharmaceuticals, Inc.
Phase 1/2
71
Oxford
2021-12-22
Active, closed
Sanofi
Phase 4
1,339
Cambridge, Oxford, Bradford, Liverpool, Newcastle upon Tyne, Wakefield
2021-12-16
Recruiting
UCB Biopharma SRL
Phase 3
350
Birmingham, Cardiff, Glasgow, London, Oxford, Salford
2021-12-07
Recruiting
Blueprint Medicines Corporation
Phase 2/3
534
Cardiff, Birmingham, London, Oxford, Plymouth
2021-11-30
Recruiting
Perspectum
Observational
600
Oxford
2021-11-15
Recruiting
Medialis Ltd.
Observational
180
Oxford
2021-11-03
Recruiting
First-in-human Study of OVM-200 as a Therapeutic Cancer Vaccine
NCT05104515Prostate Cancer, Non Small Cell Lung Cancer, Ovarian Cancer
Oxford Vacmedix UK Ltd.
Phase 1
36
London, Manchester, Oxford
2021-11-01
Recruiting
argenx
Phase 2/3
12
London, Manchester, Oxford
2021-10-26
Active, closed
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
1,899
Oxford
2021-10-20
Active, closed
Janssen Research & Development, LLC
Phase 3
587
Blackpool, Dundee, London, Oxford, Plymouth, Sutton
2021-10-14
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
London, Nottingham, Oxford
2021-10-06
Recruiting
Pfizer
Phase 3
893
Bournemouth, Oxford, Cardiff, Bristol, Canterbury, Manchester
2021-10-04
Recruiting
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
DrugPaclitaxel
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Study of INBRX-109 in Conventional Chondrosarcoma
NCT04950075Conventional Chondrosarcoma
DrugINBRX-109
Inhibrx Biosciences, Inc
Phase 2
206
London, Manchester, Oxford
2021-09-23
Active, closed
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Oxford
2021-09-09
Active, closed
Contrast-Free Magnetic Resonance Imaging for Breast Disease
NCT05006196Breast Cancer, Breast Diseases
Perspectum
Observational
1,030
Oxford
2021-07-06
Active, closed
Daiichi Sankyo
Phase 2
155
London, Nottingham, Oxford
2021-06-03
Recruiting
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
NCT04844606Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
DrugMirikizumab
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
By invitation
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Active, closed
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
Geron Corporation
Phase 3
327
London, Oxford
2021-04-12
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor
2021-04-08
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
NCT04279847Myelofibrosis, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myeloproliferative Neoplasm
DrugRuxolitinib
Incyte Corporation
Phase 1
140
Boston, Lincoln, Manchester, Oxford
2021-02-23
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Active, closed
Replimune, Inc.
Phase 1
123
Bebington, London, Oxford
2020-12-29
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
ACURATE neo2™ Post Market Clinical Follow up Study
NCT04655248Aortic Valve Stenosis, Aortic Valve Calcification, Aortic Diseases
Boston Scientific Corporation
Observational
250
Liverpool, Oxford
2020-12-16
Active, closed
Amgen
Phase 3
135
Leeds, London, Newcastle, Oxford
2020-12-04
Active, closed
AstraZeneca
Phase 3
957
Cambridge, Dundee, Glasgow, Leicester, London, Manchester, Oxford, Surrey
2020-11-17
Active, closed
AstraZeneca
Phase 1/2
702
Cambridge, Manchester, Oxford, Sutton
2020-11-12
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Brighton, Leicester, Oxford
2020-10-15
Recruiting
Medialis Ltd.
Observational
100
Oxford
2020-10-07
Active, closed
argenx
Phase 2
229
London, Oxford, Sheffield
2020-09-18
Active, closed
AbbVie
Phase 3
531
Plymouth, Poole, London, Oxford, Cardiff, Aberdeen, Birmingham, Bristol
2020-09-10
Recruiting
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
NCT04256317Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
DrugsVenclexta·Azacitidine·Venetoclax
Taiho Oncology, Inc.
Phase 2/3
316
London, Maidstone, Manchester, Oxford, Southampton
2020-05-21
Active, closed
GlaxoSmithKline
Phase 3
325
Airdrie, Dundee, Edinburgh, London, Nottingham, Oxford, Plymouth, Stoke-on-Trent
2020-04-02
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
886
Glasgow, London, Oxford, Plymouth, Preston, Sheffield, Southampton
2020-03-30
Active, closed
Immunocore Ltd
Phase 1/2
410
London, Oxford, Glasgow, Liverpool, Manchester, Surrey Quays
2020-02-25
Active, closed
Eli Lilly and Company
Phase 3
58
Bristol, Liverpool, London, Oxford, Sheffield
2020-02-12
Active, closed
Hoffmann-La Roche
Phase 2/3
325
London, Northwood, Oxford, Plymouth
2020-01-29
Active, closed
Perspectum
Observational
135
Liverpool, Oxford, London
2020-01-27
Active, closed
GlaxoSmithKline
Phase 1
118
Leicester, Oxford, Southampton
2019-12-18
Recruiting
Terumo Aortic Global Endovascular Registry
NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery
Vascutek Ltd.
Observational
1,000
Derby, Hull, Manchester, Oxford
2019-12-17
Recruiting
Sumitomo Pharma America, Inc.
Phase 1/2
240
Lincoln, London, Oxford
2019-12-16
Active, closed
AbbVie
Phase 1/2
218
Oxford
2019-11-06
Active, closed
Replimune, Inc.
Phase 1
36
Bebington, London, Oxford
2019-10-17
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Southampton, Oxford, Brighton
2019-10-03
Recruiting
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
NCT04104776Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
DrugsTulmimetostat·Enzalutamide
Novartis Pharmaceuticals
Phase 1/2
300
Bath, Leicester, London, Manchester, Oxford, Southampton, Sutton, Taunton
2019-09-18
Active, closed
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
NCT04079166Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
DrugsDNA vaccine·ImmunoBody
Scancell Ltd
Phase 2
173
Cambridge, Cardiff, Leeds, London, Manchester, Northwood, Nottingham, Oxford
2019-08-19
Active, closed
Janssen Research & Development, LLC
Phase 2/3
118
Leeds, Liverpool, London, Oxford, Plymouth, Southampton
2019-08-15
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Aberdeen, Leeds, London, Oxford, Sutton in Ashfield
2019-08-12
Active, closed
Bristol-Myers Squibb
Phase 3
839
London, Oxford
2019-08-05
Active, closed
Amgen
Phase 3
457
Cardiff, Glasgow, Liverpool, London, Manchester, Oxford
2019-07-19
Recruiting
HighLife SAS
Not applicable
120
Belfast, Brighton, Edinburgh, Leeds, Leicester, London, Oxford
2019-05-28
Active, closed
AstraZeneca
Phase 3
810
Bristol, Cambridge, London, Manchester, Oxford, Romford, Sheffield
2019-04-16
Recruiting
Eli Lilly and Company
Phase 3
190
Bristol, Liverpool, London, Oxford, Sheffield
2019-04-05
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Luton, Glasgow, Sheffield, London, Oxford
2018-12-28
Active, closed
AstraZeneca
Phase 1/2
243
Cambridge, London, Manchester, Oxford
2018-12-21
Active, closed
Merck Sharp & Dohme LLC
Phase 2
329
Oxford, Manchester, Newcastle upon Tyne, Sheffield
2018-12-12
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Truro, Sutton, Cardiff, London, Nottingham, Oxford, Preston, Stoke-on-Trent
2018-12-07
Active, closed
AbbVie
Phase 2
270
London, Nottingham, Oxford, Birmingham
2018-10-10
Active, closed
Exelixis
Phase 3
187
Birmingham, Bristol, London, Oxford, Aberdeen, Glasgow, Cardiff, Manchester
2018-10-05
Active, closed
AbbVie
Phase 3
1,533
London, Oxford, Dundee, Glasgow, Leeds
2018-08-09
Active, closed
Eli Lilly and Company
Phase 3
1,058
Bury, London, Oxford
2018-07-18
Active, closed
Genentech, Inc.
Phase 1
123
Oxford
2018-06-06
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
890
Oxford, Sutton, London, Manchester
2018-05-21
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Airdrie, Bristol, Cardiff, London, Oxford
2018-05-03
Active, closed
AbbVie
Phase 3
1,336
Cambridge, Exeter, Hull, Edinburgh, Glasgow, London, Manchester, Oxford
2018-04-09
Active, closed
Acerta Pharma BV
Phase 1
12
Birmingham, Bournemouth, Cardiff, Leeds, London, Nottingham, Oxford, Southampton
2018-01-31
Active, closed
EBR Systems, Inc.
Not applicable
300
Liverpool, London, Manchester, Middlesbrough, Oxford
2018-01-17
Active, closed
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
NCT03386513Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm
DrugIMGN632
AbbVie
Phase 1/2
179
Oxford
2018-01-02
Active, closed
Pfizer
Phase 3
1,054
Plymouth, Oxford, Glasgow, Bebington, Cornwall, Liverpool, London
2017-12-18
Active, closed
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
NCT03767348Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
DrugsVusolimogene Oderparepvec·Opdivo·Nivolumab
Replimune, Inc.
Phase 2
340
Leeds, Oxford, Glasgow, Bebington, London, Southampton
2017-09-20
Active, closed
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, Middlesbrough, Oswestry, Oxford, Wigan
2017-09-19
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Sheffield, Glasgow, London, Gloucester, Oxford
2017-06-26
Active, closed
DePuy Orthopaedics
Not applicable
400
Basingstoke, Kirkcaldy, Leeds, North Yorks, Oswestry, Oxford, Wigan
2017-05-30
Active, closed
Celgene
Phase 1/2
466
Birmingham, Leeds, Oxford, Sutton
2016-10-14
Active, closed
Tesaro, Inc.
Phase 1
729
Newcastle upon Tyne, Aberdeen, London, Manchester, Oxford, Sutton
2016-03-07
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Carlisle, Dundee, Glasgow, London, Newcastle upon Tyne, Oxford, Plymouth, Scunthorpe
2015-11-27
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,503
Aberdeen, Birmingham, Bristol, Derby, Glasgow, Oxford, Plymouth, Preston
2015-11-19
Active, closed
On-X Life Technologies, Inc.
Observational
510
Blackpool, Hull, London, Oxford, Southampton
2015-11-10
Active, closed
Taiho Oncology, Inc.
Phase 1/2
253
Leicester, Southampton, Oxford, Sutton, Birmingham, Glasgow, London, Manchester
2015-07-14
Active, closed
Acerta Pharma BV
Phase 2
124
Cardiff, Leeds, Leicester, Nottingham, Oxford, Plymouth, Southampton
2015-03-02
By invitation
Registry of Patients With Hypophosphatasia
NCT02306720Hypophosphatasia (HPP)
Alexion Pharmaceuticals, Inc.
Observational
1,571
Bristol, London, Leicester, Stanmore, Oxford, Sheffield, Newcastle upon Tyne, Birmingham
2015-01-20
Active, closed
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT02264678Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
DrugsSaruparib·Olaparib·Durvalumab·Carboplatin
AstraZeneca
Phase 1
358
Bristol, Cambridge, Coventry, London, Manchester, Oxford, Sutton, Withington
2014-10-31
Active, closed
Acerta Pharma BV
Phase 2
107
Bournemouth, Leeds, Leicester, London, Oxford, Plymouth, Southampton
2014-09-11
Recruiting
Boston Scientific Corporation
Observational
1,500
Bristol, Glasgow, Liverpool, London, Newcastle, Oxford
2014-03-04
Active, closed
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
NCT02029443Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
DrugAcalabrutinib
Acerta Pharma BV
Phase 1/2
306
Leeds, London, Oxford
2014-01-30
Active, closed
Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study
NCT03343171Osteoarthritis, Avascular Necrosis, Inflammatory Arthritis, Post-traumatic Arthritis
Zimmer Biomet
Observational
203
Glasgow, Oxford, Southampton
2010-09-15
Active, closed
AstraZeneca
Phase 1
197
Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton
2008-10-27
Rows per page Showing 1–372 of 372
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-uk/city/oxford

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the UK and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,863 studies in total at the last sync on 11 Oct 2026, 03:15 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 372 of those studies with a site in Oxford.

How many clinical trials are recruiting in Oxford?

185 of the 372 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:15 UTC sync. A further 5 have not yet opened recruitment, 171 are active but closed to new participants, and 11 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Oxford), 372 studies
PhaseStudiesRecruitingShare
Phase 31557541.7%
Phase 2723019.4%
Phase 1/236239.7%
Phase 135179.4%
Observational32178.6%
Not applicable19105.1%
Phase 2/31694.3%
Phase 4741.9%

Most active sponsors

Lead sponsors with the most studies (Oxford)
Lead sponsorStudiesRecruiting
AstraZeneca2012
AbbVie175
Hoffmann-La Roche178
Eli Lilly and Company1510
Merck Sharp & Dohme LLC139
Novartis Pharmaceuticals135
Bristol-Myers Squibb126
Sanofi115
argenx104
Janssen Research & Development, LLC94
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.